Overview
The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy
Status:
Unknown status
Unknown status
Trial end date:
2019-12-01
2019-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of this study is to investigate the occurrence of AKI during antiviral therapy, when compared with baseline values in Egyptian patients. In addition, the study aims to evaluate the change in insulin resistance value after treating patients from HCV.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
MTI UniversityTreatments:
Antiviral Agents
Sofosbuvir
Criteria
Inclusion Criteria:- Ageā„ 18 years Chronic infection with HCV GT 4 No prior HCV treatment experience
Exclusion Criteria:
- Co-infection with HBV or HIV, clinical evidence of ischemic heart disease, the
presence of diabetic ketoacidosis, Patients admitted to the intensive care unit (ICU),
or expected to undergo surgery during the study period, and Child Pough score C.